Search research articles
Contact Us
Filters
Showing results (11-20 of 490) with videos related to
Page
of 49
Sort By:
The New England Journal of Medicine
|
May 21, 2005
Treatment of myelodysplastic syndromes
Michael Stadler, Arnold Ganser
Current Opinion in Hematology
|
December 9, 2016
Therapy-related myeloid neoplasms
Arnold Ganser, Michael Heuser
Seminars in Hematology
|
July 17, 2007
Risks and benefits of erythropoiesis-stimulating agents in cancer management
Gernot Beutel, Arnold Ganser
Annals of Hematology
|
August 4, 2005
Recombinant human erythropoietin in the treatment of nonrenal anemia
Michael Heuser, Arnold Ganser
Expert Review of Hematology
|
September 9, 2024
Relapse and resistance in acute myeloid leukemia post venetoclax: improving second lines therapy and combinations
Rabia Shahswar, Arnold Ganser
Current Treatment Options in Oncology
|
July 1, 2020
Treatment of Relapsed Acute Myeloid Leukemia
Felicitas Thol, Arnold Ganser
The Lancet. Haematology
|
September 3, 2017
Predicting death in patients with acute graft-versus-host disease after reduced-intensity conditioning
Eva M Weissinger, Arnold Ganser
Current Opinion in Oncology
|
October 9, 2008
Erythropoietin in cancer-related anemia
Martin H Fenner, Arnold Ganser
Hematology (Amsterdam, Netherlands)
|
June 16, 2001
The AML1/MTG8 Fusion Transcript in t(8;21) Positive AML and its Implication for the Detection of Minimal Residual Disease; Malignancy
JÜrgen Krauter, Gerhard Heil, Arnold Ganser
Blood
|
November 9, 2023
How I treat refractory and relapsed acute myeloid leukemia
Felicitas Thol, Hartmut Döhner, Arnold Ganser
Page
of 49
Search research articles
Search
Showing results (11-20 of 490) with videos related to
Sort By:
Page
of 49
The New England Journal of Medicine
|
May 21, 2005
Treatment of myelodysplastic syndromes
Michael Stadler, Arnold Ganser
Current Opinion in Hematology
|
December 9, 2016
Therapy-related myeloid neoplasms
Arnold Ganser, Michael Heuser
Seminars in Hematology
|
July 17, 2007
Risks and benefits of erythropoiesis-stimulating agents in cancer management
Gernot Beutel, Arnold Ganser
Annals of Hematology
|
August 4, 2005
Recombinant human erythropoietin in the treatment of nonrenal anemia
Michael Heuser, Arnold Ganser
Expert Review of Hematology
|
September 9, 2024
Relapse and resistance in acute myeloid leukemia post venetoclax: improving second lines therapy and combinations
Rabia Shahswar, Arnold Ganser
Current Treatment Options in Oncology
|
July 1, 2020
Treatment of Relapsed Acute Myeloid Leukemia
Felicitas Thol, Arnold Ganser
The Lancet. Haematology
|
September 3, 2017
Predicting death in patients with acute graft-versus-host disease after reduced-intensity conditioning
Eva M Weissinger, Arnold Ganser
Current Opinion in Oncology
|
October 9, 2008
Erythropoietin in cancer-related anemia
Martin H Fenner, Arnold Ganser
Hematology (Amsterdam, Netherlands)
|
June 16, 2001
The AML1/MTG8 Fusion Transcript in t(8;21) Positive AML and its Implication for the Detection of Minimal Residual Disease; Malignancy
JÜrgen Krauter, Gerhard Heil, Arnold Ganser
Blood
|
November 9, 2023
How I treat refractory and relapsed acute myeloid leukemia
Felicitas Thol, Hartmut Döhner, Arnold Ganser
Page
of 49